Patrick Daly

DocwireNews

According to Jing Wang and collaborating researchers, the combination of sintilimab and decitabine is relative safe and exhibits anti-tumor activity in patients with treatment-na&iuml;ve high-risk myelodysplastic syndrome (MDS). The single-arm, open-label clinical trial was presented at the 2022 American Society of Clinical Oncology Annual Meeting.A total of 21 patients were enrolled at the time of the poster submission. The intervention regimen included decitabine 20 mg/m2 intravenously (IV) daily for five days, and sintilimab 200 mg IV on days one and 22 of 42-day cycles, over a maximum of eight cycles. The primary measure of the study was objective response rate (ORR). Secondary outcomes included the safety and survival profiles of the regimen.Over a median follow-up of 5.8 months, the authors observed an ORR of 64%, with six of 21 patients achieving a complete response, four achieving a marrow complete response, four achieving hematologic improvement, and three achieving both a marrow complete response and hematologic improvement.Regarding safety, the most common grade III treatment-emergent adverse events (TEAEs) were febrile neutropenia (76.2%) and pulmonary infection (38.1%). Twelve patients experienced immune-related adverse events included rash (28.6%), pneumonia (9.5%), hypothyroidism (9.5%), elevated serum bilirubin (4.8%), and transpeptidase (4.8%). In these patients, ASXL1 (28.6%), RUNX1 (14.3%), and TET2 (14.3%) were the most frequently mutated genes. No grade IV TEAEs or treatment-related deaths were observed.This trial was, to the authors&rsquo; knowledge, the first to evaluate the combination of sintilimab and decitabine for untreated higher-risk MDS. Based on their preliminary findings, they judged the combination regimen to have manageable toxicities and viable activity.

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Combined HMA and PD-1 Antibody Regimen in Myelodysplastic Syndrome

ASCO 2022

According to Jing Wang and collaborating researchers, the combination of sintilimab and decitabine is relative safe and exhibits anti-tumor activity in patients with ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe